Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
about
Prostaglandin E2 signals through PTGER2 to regulate sclerostin expressionTwenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studiesBone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator functionControl of the SOST bone enhancer by PTH using MEF2 transcription factorsInactivation of Lrp5 in osteocytes reduces young's modulus and responsiveness to the mechanical loadingLrp5 functions in bone to regulate bone massWnt modulators in the biotech pipelineDistinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathwaysWnt/beta-catenin signaling: components, mechanisms, and diseasesWnts talking with the TGF-β superfamily: WISPers about modulation of osteoarthritisWNT signaling in bone development and homeostasisThe DAN family: modulators of TGF-β signaling and beyondControl of bone mass and remodeling by PTH receptor signaling in osteocytesCharacterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATIONCrystal structures of the extracellular domain of LRP6 and its complex with DKK1Structural Basis of Wnt Signaling Inhibition by Dickkopf Binding to LRP5/6Structure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein AntagonismWnt signaling in bone and muscleWNT signaling in bone homeostasis and disease: from human mutations to treatmentsRegulation of Wnt/β-catenin signaling within and from osteocytesDissecting molecular differences between Wnt coreceptors LRP5 and LRP6Genetic evidence that SOST inhibits WNT signaling in the limbMutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibitionGeneration and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivoLrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.Lrp4 modulates extracellular integration of cell signaling pathways in development.Wise regulates bone deposition through genetic interactions with Lrp5Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.Wnt-β-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage.Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin.Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblastsSclerostin: current knowledge and future perspectives.Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.Emerging therapeutic opportunities for skeletal restoration.SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease.Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use
P2860
Q21560844-F9245A46-0EC8-476A-82EA-D69765ED688DQ24289320-3AC839FF-7C5A-424D-AD72-C94C5E9118ACQ24299076-36C29336-78F5-40FC-B5D0-A3A959128729Q24337339-FDB9349E-5463-408C-AC43-6C2D4C63D91DQ24601727-9739EEE0-1C7A-4B27-9EE6-B245B29C9C72Q24615653-041BD2A5-19C4-418A-8FD7-1ACB3CE9D9A2Q24618567-52775EEC-F051-4E77-870B-9A43829904F8Q24621990-A61C963E-ED67-408A-8F99-E5D0D8C57015Q24630938-9486D382-3D5D-45D7-B5A6-EE0D06A4ACF2Q26775922-BCC32C95-5AE5-42D4-A0CF-BC04AB08B0DBQ27008570-7C4FC6AE-21A2-47DB-ABE3-55379118B22FQ27025762-FBA0ACAA-D64D-4CBB-89A7-F70343BD9A68Q27300741-644A8AEA-C474-4754-BD31-8F6CDF469EBBQ27653715-EBE7E535-5FBE-48A1-A1D7-2CEEDFDC1C28Q27674857-69FF6146-4355-41D8-9408-92ADC5C94258Q27675072-68673BFD-F5B9-494F-8AE8-88FB0025E2E7Q27679073-19011450-E035-4E44-8835-5842CB4F7C65Q27687077-4DC6B8B8-3224-4158-9126-AA511CD762C2Q28285090-068F34BF-A069-493C-BB1B-2D0FFB9A2DCFQ28286814-0D789F88-590A-4907-8E7E-1DB5E3CFA22AQ28476670-0AC4B8F1-0815-42CF-AD0A-017B659C3092Q28509512-1DF7CD7C-F8CD-4A86-B7BF-74BD8DDF3162Q28535490-B17C3845-E09A-452F-8971-F25833FA3651Q30497635-CF441CD1-CB71-44F1-817B-9FE3A6F08022Q30914003-314962CB-C07E-4B5F-BA45-266EFF34A6DAQ33396675-1BAF87EF-1035-47A8-ACFE-9A325E1635A2Q33553692-5B89994D-D4BD-4D41-8523-6F1C91CABA5FQ33564617-A090C496-0E93-4A1E-92A8-32C7F0F1821EQ33570529-CB716268-A10B-48F1-9B6D-72B89586779FQ33673894-0CF7799A-36F8-4FCB-AAC8-A708150829C6Q33720166-ACACB09D-FB5C-4877-812E-6EE2A86843DBQ33786865-30C55B8D-8E67-4A96-BB4E-7913F475D63BQ33895465-65B42F30-9176-414D-8C7B-E40225808B7CQ33992612-44F5038F-F247-45FF-AD9A-94FC97343C3BQ34036439-60AA0238-9673-4EFA-9445-51792C3BB937Q34161867-BCA4E5FF-287D-4499-B839-25EB320111E4Q34181023-4DCB8F71-8741-470E-9306-01F3CA3AABDAQ34260123-04FBB9C4-0537-4F67-A522-3CB0D49778E6Q34408710-A2FDA80C-E666-432F-8D86-A2153E145423Q34451418-CD5F94F5-714E-441A-A427-3EA8C53C1654
P2860
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@ast
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@en
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@nl
type
label
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@ast
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@en
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@nl
prefLabel
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@ast
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@en
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@nl
P2093
P356
P1476
Bone density ligand, Sclerosti ...... G171V to modulate Wnt activity
@en
P2093
Beth Viviano
Debra L Ellies
Jean-Philippe Rey
John McCarthy
Robb Krumlauf
Scott Saunders
P304
P356
10.1359/JBMR.060810
P407
P577
2006-11-01T00:00:00Z